6744.TWO Feng Chi Biotech Corp.
- Market cap
- TWD 189M
- P/E
- 18.8x
- P/B
- 0.83x
- ROE
- 6.0%
- Dividend yield
- 7.76%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 6744.TWO undervalued?
Graham number6744.TWO trades 16.5% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Feng Chi Biotech Corp. fundamental analysis
No fundamental analysis for Feng Chi Biotech Corp. yet.
Feng Chi Biotech Corp. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Feng Chi Biotech Corp.
Feng Chi Biotech Corp. engages in the wholesale and retail of medical devices and precision instruments and biotechnology services in Taiwan and internationally. The company provides preimplantation genetic testing, prenatal testing, precision medicine, newborn screening, food/pharmaceutical microbiological testing, and medical translational research services, as well as infectious disease detection services. It also distributes various genetic and medical testing services. …
Full company profileFeng Chi Biotech Corp. financial statements
Feng Chi Biotech Corp. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 174M | 179M | 183M | 193M | 181M | 171M | 177M |
| Gross Profit | 72.2M | 85.9M | 86.1M | 83.4M | 79.6M | 77.2M | 79.2M |
| Operating Income | 20.1M | 28.6M | 26.4M | 27.1M | 24.2M | 16.1M | 13.8M |
| EBITDA | 27.6M | 39.9M | 37.0M | 36.8M | 34.8M | 29.8M | 29.2M |
| Net Income | 17.4M | 25.4M | 23.1M | 24.6M | 22.8M | 16.6M | 14.5M |
| EPS | 1.16 | 1.64 | 1.50 | 1.60 | 1.47 | 1.07 | 0.94 |
| Balance Sheet | |||||||
| Total Assets | 267M | 284M | 287M | 308M | 301M | 299M | 288M |
| Total Liabilities | 53.8M | 58.9M | 56.2M | 72.5M | 63.0M | 59.2M | 48.0M |
| Shareholders' Equity | 214M | 225M | 231M | 236M | 238M | 240M | 240M |
| Cash & Short-term Investments | 200M | 220M | 231M | 235M | 216M | 208M | 17.4M |
| Total Debt | 7.91M | 5.26M | 2.55M | 13.5M | 10.8M | 8.15M | - |
| Cash Flow | |||||||
| Operating Cash Flow | 23.6M | 39.3M | 32.9M | 28.5M | 15.4M | 25.0M | 3.24M |
| Capital Expenditure | 4.42M | 3.07M | 1.10M | 260K | 1.40M | 14.6M | 13.1M |
| Free Cash Flow | 19.2M | 36.2M | 31.8M | 28.2M | 14.0M | 10.5M | -9.89M |
| Ratios | |||||||
| ROE | 8.1% | 11.3% | 10.0% | 10.4% | 9.6% | 6.9% | 6.0% |
| ROA | 6.5% | 8.9% | 8.1% | 8.0% | 7.6% | 5.5% | 5.0% |
| Net Profit Margin | 10.0% | 14.2% | 12.7% | 12.7% | 12.6% | 9.7% | 8.2% |
| Debt to Equity | 0.04x | 0.02x | 0.01x | 0.06x | 0.05x | 0.03x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Feng Chi Biotech Corp. dividends
- Dividend yield
- 7.76%
- Forward dividend
- 0.84 TWD
- Payout ratio
- 101.1%
- Ex-dividend date
- Jul 21, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | TWD 14.6M | 0.95 | 101.1% |
| 2024 | TWD 16.2M | 1.05 | 97.4% |
| 2023 | TWD 20.8M | 1.34 | 91.2% |
| 2022 | TWD 19.3M | 1.25 | 78.2% |
| 2021 | TWD 17.7M | 1.15 | 76.6% |
| 2020 | 13.9M | 0.90 | 54.6% |
| 2019 | 13.2M | 0.88 | 76.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Feng Chi Biotech Corp.
Ownership data of Feng Chi Biotech Corp. is not available yet.
Feng Chi Biotech Corp. company profile
- Company name
- Feng Chi Biotech Corp.
- Ticker
- 6744.TWO
- ISIN
- TW0006744006
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- 1, No.5, Shaoxing North Street, Taipei, Taiwan, 100
- Phone
- 886 2 2351 9800
- Website
- fcbiotech.com.tw
About Feng Chi Biotech Corp.
Feng Chi Biotech Corp. engages in the wholesale and retail of medical devices and precision instruments and biotechnology services in Taiwan and internationally. The company provides preimplantation genetic testing, prenatal testing, precision medicine, newborn screening, food/pharmaceutical microbiological testing, and medical translational research services, as well as infectious disease detection services. It also distributes various genetic and medical testing services. The company was founded in 1992 and is based in Taipei, Taiwan.
Feng Chi Biotech Corp. management
2- Hong-Ming ZhangChairman, GM & Manager
- Mei-Zhen LuAccounting Supervisor